Elizabeth L Carpenter
Overview
Explore the profile of Elizabeth L Carpenter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Decar S, Carpenter E, Adams A, Chick R, Clifton G, Stojadinovic A, et al.
Cancer Treat Res Commun
. 2024 Sep;
41:100843.
PMID: 39305541
Background: The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from dendritic cells (DC) loaded ex vivo with autologous tumor lysate (TL). TLPLDC has been shown to decrease...
2.
Carpenter E, Van Decar S, McCarthy P, Valdera F, Adams A, OShea A, et al.
J Surg Oncol
. 2024 May;
130(1):109-116.
PMID: 38801055
Background: The benefit of adjuvant therapy (AT) remains unclear in pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT) and surgical resection. Methods: The 2019 National Cancer Database was queried for...
3.
Valdera F, OShea A, Smolinsky T, Carpenter E, Adams A, McCarthy P, et al.
J Surg Oncol
. 2023 Oct;
129(2):244-253.
PMID: 37800378
Introduction: Adjuvant (A) multiagent chemotherapy (MC) is the standard of care for patients with pancreatic adenocarcinoma (PDAC). Tolerating MC following a morbid operation may be difficult, thus neoadjuvant (NA) treatment...
4.
Spitzer H, Kemp Bohan P, Carpenter E, Adams A, Chang S, Grunkemeier G, et al.
Ann Surg Oncol
. 2023 Jun;
30(11):6662-6670.
PMID: 37330447
Background: Achieving optimal surgical outcomes in pancreatic adenocarcinoma requires a combination of both curative-intent resection to oncologic standards and stage-specific neoadjuvant or adjuvant therapy. This investigation sought to examine factors...
5.
McCarthy P, Valdera F, Smolinsky T, Adams A, OShea A, Thomas K, et al.
Front Immunol
. 2023 Mar;
14:1090533.
PMID: 36960052
Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer...
6.
Carpenter E, Valdera F, Chauviere M, Krell R
J Surg Res
. 2023 Mar;
287:63-71.
PMID: 36868125
Introduction: Total abdominal colectomy (TAC) with ileostomy is the standard treatment for severe ulcerative colitis (UC). Partial colectomy (PC) with colostomy may present a less morbid treatment option. Methods: The...
7.
Carpenter E, Flinn A, Schechtman D, Adams A, Clifton G, Krell R, et al.
Obes Surg
. 2023 Jan;
33(4):1307-1308.
PMID: 36715967
No abstract available.
8.
Elmore C, Blackstone S, Carpenter E, de Cortez P, ODonnell C, Uhlmann E, et al.
J Health Care Poor Underserved
. 2022 Dec;
33(4S):25-43.
PMID: 36533457
Introduction: Multi-sector outreach collaborations have the potential to improve COVID-19 vaccine access among underserved populations, including refugees. Methods: Using a four-pronged strategy, we offered the local refugee community COVID-19 vaccine...
9.
Kemp Bohan P, Chang S, Grunkemeier G, Spitzer H, Carpenter E, Adams A, et al.
Ann Surg Oncol
. 2022 Dec;
30(3):1436-1448.
PMID: 36460898
Background: High-volume centers (HVC), academic centers (AC), and longer travel distances (TD) have been associated with improved outcomes for patients undergoing surgery for pancreatic adenocarcinoma (PAC). Effects of mediating variables...
10.
Carpenter E, Adams A, McCarthy P, Chick R, Spitzer H, Nelson D, et al.
Mil Med
. 2022 Sep;
188(7-8):e1558-e1562.
PMID: 36111895
Introduction: The 2020 Commission on Cancer accreditation standards 5.7 and 5.8 address total mesorectal excision for rectal cancer and lymph node sampling for lung cancer. The purpose of this review...